A team of researchers at Belgium-based life sciences research institute VIB and KU Leuven has uncovered why people with a hereditary form of Parkinson’s disease suffer from sleep disturbances. The molecular mechanisms uncovered in fruit flies and human stem cells also point to candidate targets for the development of new treatments.
Parkinson’s disease typical symptoms are related to movement difficulty, such as tremor, rigidity, and loss of balance. But patients are also faced with several non-motor symptoms, including disturbed sleep. Nearly all patients experience some form of sleep pattern disturbance, ranging from nocturnal movements or insomnia to daytime sleepiness.
Problems with sleeping patterns are one of the earliest symptoms of the disease, sometimes occurring as much as 10 years prior to the onset of motor symptoms and often before the actual diagnosis is made.
Using induced human pluripotent stem cells derived from people with a hereditary form of Parkinson’s disease, as well as genetically modified fruit flies with Parkinson’s symptoms, a team of scientists lead by Patrik Verstreken of VIB-KU Leuven Center for Brain & Disease Research uncovered problems with the so-called neuropeptidergic neurons, a specific type of neurons that regulate sleeping patterns.
Abnormal lipid trafficking in these neurons disrupts the production and release of neuropeptides, which in turn affects the regulation of sleep and circadian rhythms. The result is a disturbed sleep-wake cycle in the genetically modified flies.
“We uncovered which type of lipid is missing, so we could try to rescue the sleep pattern defects by restoring the lipid balance,” says Jorge Valadas, part of the Verstreken team, in a release. “When we model Parkinson’s disease in fruit flies, we find that they have fragmented sleep patterns and difficulties in knowing when to go to sleep or when to wake up. But when we feed them phosphatidylserine—the lipid that is depleted in the neuropeptidergic neurons—we see an improvement in a matter of days.”
The findings are promising, but the scientists underscore that a lot of work needs to be done before the results can be translated to patients.
Verstreken says, “Translating the phosphatidylserine experiments is not straightforward, as similar sleep manifestations are absent in mouse models of Parkinson’s disease. The good news is that phosphatidylserine is already marketed as a food supplement, so if we can prove efficacy in humans, this would be very good news. There are still a lot of questions though. For example, we don’t know if phosphatidylserine could be delivered to the brain in humans, or at which dose.”
Non-motor symptoms often receive less attention, but nonetheless have a major impact on patients’ lives. Understanding and potentially intervening in what causes sleep problems in Parkinson’s disease is thus an important step forward, but, according to Verstreken, the findings are also a real conceptual game changer: “The main culprits of the motor symptoms are dopaminergic neurons, but the circadian rhythm and sleep pattern problems are specific to defects in neuropeptidergic neurons. Unlike for dopaminergic neurons, the neuropeptidergic problems are caused by neuronal dysfunction, not degeneration, which implies that they can be corrected. This could be a real paradigm shift in the Parkinson’s disease field.”
The study is published in Neuron.